Brief: FDA Grants Breakthrough Therapy Designation To NS-089/NCNP-02 For The Treatment Of Duchenne Muscular Dystrophy

Nippon Shinyaku

27/07/2023 15:16

July 27 (Reuters) - Nippon Shinyaku Co Ltd  4516.T :
    * FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO
NS-089/NCNP-02
FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
    * NS PHARMA- CLINICAL DEVELOPMENT OF NS-089/NCNP-02 INCLUDES
PLANNED PHASE 2 STUDY IN US AND A PHASE 2 STUDY CONDUCTED IN
JAPAN BY

Source text for Eikon:  ID:nPnbkh747a 
Further company coverage:  4516.T 

 ((Reuters.Briefs@thomsonreuters.com;))